Literature DB >> 15300661

Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A.

Bernhard Voller1, Ekaterina Moraru, Eduard Auff, Michael Benesch, Werner Poewe, Jörg Wissel, Jörg Müller, Tanja Entner, Hans Bigalke, Peter Schnider.   

Abstract

Approximately 5% of patients with cervical dystonia receiving repeated botulinum neurotoxin A (BoNT/A) injections develop secondary loss of treatment benefit. Currently available tests to directly detect neutralizing BoNT/A antibodies (BoNT/A-AB) are either expensive or time consuming. To establish a simple, clinically useful test for antibody detection, we adapted the ninhydrin sweat test (NST). Eighteen dystonic patients with secondary nonresponse and clinically suspected BoNT/A-AB formation were tested for BoNT/A-AB in the mouse diaphragm test (MDT). In addition, the size of the anhidrotic area was determined by the NST 21 days after an intradermal dose of 10 U Dysport into the hypothenar region of the left palm. In nine patients, positive BoNT-AB titers were found in the MDT. There was a significant correlation between the BoNT/A-AB titers and the anhidrotic area (Spearman's rho = -0.9, P < 0.0001). Both tests provided comparably good results with respect to qualitative antibody detection. In the clinical situation of secondary nonresponse to BoNT/A therapy, the economical NST may be a helpful tool to detect neutralizing BoNT/A-AB. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300661     DOI: 10.1002/mds.20073

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.

Authors:  Harald Hefter; Constanze Spiess; Dietmar Rosenthal
Journal:  J Neural Transm (Vienna)       Date:  2013-12-06       Impact factor: 3.575

Review 3.  Immunogenicity Associated with Botulinum Toxin Treatment.

Authors:  Steven Bellows; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

4.  Immunogenicity of botulinum toxin.

Authors:  Syeo Young Wee; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2022-01-15

Review 5.  Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.

Authors:  Warner W Carr; Neal Jain; J Wesley Sublett
Journal:  Adv Ther       Date:  2021-09-13       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.